Thanks for pointing out the move out to the regulatory filing stage, had missed that.
I'm focused on HLHS because at the Annual meeting there was a pause and an exchange of looks before Silviu said they were pursuing HLHS first for strategic reasons. It stood out because of the body language.
Anyone else who was there care to comment?
It's possible that is still the strategy but with no mention in the announcement I would think it's been parked. WHY?
Reg
Ann: Meeting Requested with FDA on Revascor Accelerated Approval, page-39
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.64 |
Change
-0.030(1.80%) |
Mkt cap ! $2.095B | |||
| Open | High | Low | Value | Volume |
| $1.67 | $1.67 | $1.62 | $23.20M | 14.15M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 217849 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 69336 | 2 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |